Biotech Portfolio Expansion
Vertex to Acquire Crinetics for $10 Billion, Expanding Rare Disease Portfolio
Key Points
UBS highlights Crinetics as potentially having multiple catalysts in its pipeline with a high likelihood of success, including Atumelnant in Phase 3 for congenital adrenal hyperplasia, and models peak sales for Atumelnant around $2.0 billion.
Crinetics stock technicals, as of the coverage, show the shares around $42.03, trading above the MA-20, MA-50, and MA-200, with RSI in overbought territory and a near-term trading range of roughly $41.50–$44.00 and a less-than-20% probability of further upside.
Crinetics surged about 100% in after-hours trading on the deal announcement, while Vertex traded down roughly 2.3%.
GuruFocus provides context on Vertex's scale and valuation ahead of the deal, noting a market cap around $134.41 billion and a price/earnings ratio of about 31.41x, with further detail on Vertex's GF Score framework.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about $10 billion, paying $85 per share in cash — a deal that sent Crinetics stock surging roughly 100% in after-hours trading, according to Yahoo Finance. Vertex shares dipped about 2.3% on the news. The companies expect to close the deal in the third quarter of 2026.
The acquisition is Vertex's largest ever, according to Fierce Pharma. It gives Vertex control of two drugs targeting rare hormonal disorders. Vertex says the combined assets could generate more than $5 billion in peak annual sales, according to Benzinga.
Palsonify and Atumelnant Drive the $10 Billion Bet
The deal centers on two drugs. The first is Palsonify, a once-daily oral pill for acromegaly — a rare condition where the body makes too much growth hormone. The FDA approved Palsonify in 2025, giving it a head start in a niche but lucrative market, according to QZ.
The second is atumelnant, currently in Phase 3 trials for congenital adrenal hyperplasia, a rare disorder affecting hormone production. UBS models peak sales for atumelnant alone at around $2.0 billion. Together, Vertex believes both drugs can exceed $5 billion in peak sales, per Benzinga.
Bridge Financing Backs Vertex's Biggest Deal Yet
Vertex will fund the acquisition through a mix of cash and debt. Bank of America and Morgan Stanley are providing about $4.5 billion in bridge financing, according to Yahoo Finance. The net cost, after accounting for Crinetics' cash on hand, is roughly $8.8 billion.
Vertex carries a market cap of about $134.41 billion and trades at a price-to-earnings ratio of roughly 31.41x, according to GuruFocus. The company has the scale to absorb a deal this size, but analysts noted Vertex shares fell about 2.3% on the announcement — a sign some investors want to see the pipeline deliver.
Crinetics Stock Doubled Overnight as Insiders Had Sold
Crinetics shares were trading near $42.03 before the deal broke, sitting above their 20-day, 50-day, and 200-day moving averages with the RSI in overbought territory. The $85-per-share offer represented a massive premium to that price. Shares jumped roughly 100% in after-hours trading on the news.
In the three months before the deal, Crinetics insiders sold roughly $9 million worth of shares. That timing will likely draw scrutiny, though insider sales are common ahead of strategic transactions. CRNX investors now weigh a straightforward outcome: $85 cash per share at closing, expected in mid-2026.
Vertex Reshapes Its Rare-Disease Strategy Beyond Cystic Fibrosis
Vertex built its reputation on cystic fibrosis drugs. This deal signals a push into rare endocrine disorders — conditions that affect hormones and are often underserved by existing treatments. The acquisition adds a commercial-stage product and a late-stage pipeline asset in one move, according to Fierce Pharma.
The merger agreement was set with a close date targeted for July 6, 2026, according to GuruFocus. If the deal clears regulators on schedule, Vertex will enter the second half of 2026 with two new rare-disease drugs and a much larger addressable market than it had before.
Sentiment
Mostly PositivePublishers
12
Articles
24
Reach
36
